14 Breast Cancer Clinical Trials in Anchorage, AK (2026)

Q: How do I join a clinical trial in Anchorage?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Anchorage research site will contact you.

Recruiting Breast Cancer Studies in Anchorage

NCT03053193Recruiting

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing ...

Anchorage, AK30,000 participantsAgendia

View Study Details

NCT05774951Recruiting

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk f...

Anchorage, AKPHASE34,300 participantsAstraZeneca

View Study Details

NCT05879926Recruiting

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast ...

Anchorage, AKPHASE33,960 participantsNRG Oncology

View Study Details

NCT06058377Recruiting

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-I...

Anchorage, AKPHASE33,680 participantsNational Cancer Institute (NCI)

View Study Details

NCT05929768Recruiting

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast canc...

Anchorage, AKPHASE32,400 participantsSWOG Cancer Research Network

View Study Details

NCT06401421Recruiting

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for cir...

Anchorage, AK1,800 participantsExact Sciences Corporation

View Study Details

NCT05827081Recruiting

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on in...

Anchorage, AKPHASE31,400 participantsNovartis Pharmaceuticals

View Study Details

NCT05812807Recruiting

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after p...

Anchorage, AKPHASE31,295 participantsAlliance for Clinical Trials in Oncology

View Study Details

NCT07492641Recruiting

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

The purpose of this study is to investigate the efficacy and safety of BGB-43395 in combination with letrozole compared with investigator's choice of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) in...

Anchorage, AKPHASE31,056 participantsBeOne Medicines

View Study Details

NCT07174336Recruiting

A Study of LY4064809 With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

The purpose of the study is to assess the efficacy and safety of the addition of LY4064809 to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal gr...

Anchorage, AKPHASE3920 participantsEli Lilly and Company

View Study Details

NCT03723928Recruiting

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread t...

Anchorage, AKNA739 participantsSWOG Cancer Research Network

View Study Details

NCT03418961Recruiting

S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer

This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other pl...

Anchorage, AKPHASE3491 participantsSWOG Cancer Research Network

View Study Details

NCT05896189Recruiting

Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors

This Phase III trial will examine the efficacy of computerized cognitive training methods on perceived cognitive impairment in breast cancer survivors....

Anchorage, AKNA386 participantsNRG Oncology

View Study Details

NCT06126276Recruiting

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

This phase II ComboMATCH treatment trial compares the effect of neratinib to the combination of neratinib and palbociclib in treating patients with HER2 positive solid tumors. Neratinib and palbocicli...

Anchorage, AKPHASE270 participantsNational Cancer Institute (NCI)

View Study Details

About Breast Cancer Clinical Trials in Anchorage

Breast cancer is a disease in which cells in the breast grow out of control. It is the most common cancer in women worldwide and can also occur in men. Treatment options include surgery, radiation, chemotherapy, hormone therapy, and targeted therapies.

There are currently 14 breast cancer clinical trials recruiting participants in Anchorage, AK. These studies are seeking a combined 52,497 participants. Research is being sponsored by Agendia, AstraZeneca, NRG Oncology and 7 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Breast Cancer Clinical Trials in Anchorage — FAQ

Are there breast cancer clinical trials in Anchorage?

Yes, there are 14 breast cancer clinical trials currently recruiting in Anchorage, AK. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Anchorage?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Anchorage research site will contact you about next steps.

Are clinical trials in Anchorage free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Anchorage studies also compensate for your time and travel.

What breast cancer treatments are being tested?

The 14 active trials in Anchorage are testing new therapies including novel drugs, biologics, and treatment approaches for breast cancer.

Data updated July 18, 2026 from ClinicalTrials.gov